LATE-BREAKING ABSTRACT: A randomised, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 on moderate persistent asthma
N. B. Barnes, I. P. Pavord, A. C. Chuchalin, J. B. Bell, M. H. Hunter, M. P. Payton, L. P. C. Pearce Collins, R. P. Pettipher, J. S. Steiner, M. P. Perkins (London, Leicester, Oxford, United Kingdom; Moscow, Russian Federation)
Source: Annual Congress 2009 - Novel approaches in asthma
Session: Novel approaches in asthma
Session type: Oral Presentation
Number: 3267
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. B. Barnes, I. P. Pavord, A. C. Chuchalin, J. B. Bell, M. H. Hunter, M. P. Payton, L. P. C. Pearce Collins, R. P. Pettipher, J. S. Steiner, M. P. Perkins (London, Leicester, Oxford, United Kingdom; Moscow, Russian Federation). LATE-BREAKING ABSTRACT: A randomised, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 on moderate persistent asthma. Eur Respir J 2009; 34: Suppl. 53, 3267
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Late-breaking abstract: Inhaled pan-selectin antagonist bimosiamose in COPD: A double-blind, randomized, placebo-controlled phase II study Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease Year: 2011
A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis Source: Eur Respir J 2015; 46: 1021-1032 Year: 2015
A randomized, double-blind, placebo-controlled study to evaluate the role of formoterol in management of acute asthma Source: Eur Respir J 2006; 28: Suppl. 50, 498s Year: 2006
Late Breaking Abstract - Phase 2a randomised, double-blind, placebo-controlled, crossover study of a novel P2X3 receptor antagonist S-600918 in patients with refractory chronic cough Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough Year: 2019
Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Airway hyperresponsiveness to mannitol as a predictor of treatment response to ciclesonide in patients with suspected asthma: A double-blind, randomised, placebo-controlled trial Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease Year: 2012
A randomised controlled trial of zafirlukast in acute asthma Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005
Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Methotrexate in treatment of severe difficult-to-treat asthma: randomized, double-blind, placebo-controlled study Source: Annual Congress 2007 - Towards controlling severe asthma Year: 2007
A randomized double-blind placebo-controlled trial on the short and long-term effects of electro acupuncture on moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 502s Year: 2006
A double-blind double dummy randomised placebo-controlled cross-over design clinical trial of formoterol delivered by two different dry powder devices in prevention of bronchoconstriction induced by methacholine in mild to moderate persistent asthma in adult patients Source: Annual Congress 2009 - Airway hyperresponsiveness: mechanism and assessment Year: 2009
Umeclidinium in patients with COPD: a randomised, placebo-controlled study Source: Eur Respir J 2014; 43: 72-81 Year: 2004
Nasal beclomethasone plus loratadine in patients with rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 547s Year: 2007
Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study Source: Eur Respir J, 58 (5) 2004240; 10.1183/13993003.04240-2020 Year: 2021
Effects of a concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: A placebo-controlled double-blind trial Source: Annual Congress 2010 - COPD exacerbation Year: 2010
Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
Preventive effect of carbocysteine on exacerbation of asthma, GAIA randomised, placebo-controlled multi-centre study Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
The use of modafinil in patients with obstructive apnoea-hyponoea syndrome (OAHS). A randomized, placebo-controlled, double-blind study Source: Eur Respir J 2001; 18: Suppl. 33, 419s Year: 2001
LATE-BREAKING ABSTRACT: Prevention of COPD exacerbation by lysozyme: A double-blind, randomized, placebo-controlled study Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015